Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VSTM Verastem Inc

0.10 (1.35%)
Last Updated: 12:13:22
Delayed by 15 minutes


Draw Mode:

Volume 33,524
Bid Price 7.44
Ask Price 7.57
News -
Day High 7.66


52 Week Range


Day Low 7.26
Company Name Stock Ticker Symbol Market Type
Verastem Inc VSTM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 1.35% 7.51 12:13:22
Open Price Low Price High Price Close Price Prev Close
7.43 7.26 7.66 7.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
446 33,524 $ 7.49 $ 251,140 - 3.87 - 15.18
Last Trade Time Type Quantity Stock Price Currency
12:17:36 1 $ 7.505 USD

Verastem Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
189.76M 25.27M - 2.6M -73.81M -2.92 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Verastem News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No VSTM Message Board. Create One! See More Posts on VSTM Message Board See More Message Board Posts

Historical VSTM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.477.78996.457.1785,1461.0416.07%
1 Month7.007.78995.946.6467,5160.517.29%
3 Months9.5510.29785.947.8083,450-2.04-21.36%
6 Months11.3812.005.949.00164,609-3.87-34.01%
1 Year4.6215.183.879.33906,8462.8962.55%
3 Years26.0459.223.47423.711,779,524-18.53-71.16%
5 Years55.6859.223.47423.792,343,409-48.17-86.51%

Verastem Description

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers.

Your Recent History

Delayed Upgrade Clock